Product
JT001
Aliases
VV116
6 clinical trials
2 indications
Indication
COVID-19Indication
Healthy SubjectsClinical trial
A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase II/III Study to Evaluate the Efficacy, Safety and Pharmacokinetics of JT001 (VV116) for the Early Treatment of Coronavirus Disease 2019 (COVID-19) in Participants With Mild to Moderate COVID-19.Status: Terminated, Estimated PCD: 2023-03-23
Clinical trial
A Multicenter, Single-blind, Randomized, Controlled Study to Evaluate the Efficacy and Safety of JT001 (VV116) Compared With Paxlovid for the Early Treatment of COVID-19 in Participants With Mild to Moderate COVID-19Status: Completed, Estimated PCD: 2022-05-13
Clinical trial
A Multi-center, Double-blinded, Randomized, Phase III Study to Evaluate the Efficacy and Safety of JT001 (VV116) Compared With Favipiravir in Participants With Moderate to Severe Coronavirus Disease 2019 (COVID-19)Status: Terminated, Estimated PCD: 2022-12-15
Clinical trial
An Open-label, Dose-Escalation, Multiple-Dose Phase 1 Clinical Study to Evaluate the Pharmacokinetics, Safety and Tolerability of JT001 Tablets in Caucasian Healthy Subjects After Oral AdministrationsStatus: Withdrawn, Estimated PCD: 2022-08-01
Clinical trial
A Multicenter, Double-blind, Randomized, Placebo-Controlled, Phase III Clinical Study to Evaluate the Efficacy and Safety of JT001 (VV116) in Participants With Mild to Moderate COVID-19Status: Completed, Estimated PCD: 2023-02-14
Clinical trial
A Real-world Study：Disease Outcome and Safety of JT001 in Patients With Coronavirus Disease 2019 (COVID-19)Status: Recruiting, Estimated PCD: 2024-05-31